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FatigueAn increasing body of literature indicates that chemotherapy (ChT) for breast cancer (BC) is associated with
adverse effects on the brain. Recent research suggests that cognitive and brain function in patients with BC
may already be compromised before the start of chemotherapy. This is the ﬁrst study combining neuropsycho-
logical testing, patient-reported outcomes, and multimodal magnetic resonance imaging (MRI) to examine pre-
treatment cognition and various aspects of brain function and structure in a large sample.
Thirty-two patients with BC scheduled to receive ChT (pre-ChT+), 33 patients with BC not indicated to undergo
ChT (pre-ChT−), and 38 no-cancer controls (NCs) were included. The examination consisted of a neuropsycho-
logical test battery, self-reported aspects of psychosocial functioning, and multimodal MRI.
Patients with BC reported worse scores on several aspects of quality of life, such as higher levels of fatigue and
stress. However, cortisol levels were not elevated in the patient groups compared to the control group. Overall
cognitive performance was lower in the pre-ChT+ and the pre-ChT− groups compared to NC. Further, patients
demonstrated prefrontal hyperactivation with increasing task difﬁculty on a planning task compared to NC, but
not during a memory task. White matter integrity was lower in both patient groups. No differences in regional
brain volume and brain metabolites were found. The cognitive and imaging data converged to show that
symptoms of fatigue were associated with the observed abnormalities; the observed differences were no longer
signiﬁcant when fatigue was accounted for.
This study suggests that cancer-related psychological or biological processes may adversely impact cognitive
functioning and associated aspects of brain structure and function before the start of adjuvant treatment. Our
ﬁndings stress the importance to further explore the processes underlying the expression of fatigue and to
study whether it has a contributory role in subsequent treatment-related cognitive decline.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neuropsychological and magnetic resonance imaging (MRI) studies
show the occurrence of cognitive decline and brain changes following
chemotherapy (ChT) in patients with breast cancer (BC) (Pomykala
et al., 2013). Preclinical studies support these ﬁndings and have demon-
strated increased apoptosis in healthy proliferating cells in the central
nervous system as well as damage to neural precursor cells (Seigers
et al., 2013).. This is an open access article underInterestingly, several neuropsychological studies have observed
lower than expected cognitive performance in patients with BC al-
ready before the start of adjuvant treatment (Lange et al., 2014;
Wefel and Schagen, 2012). A small number of MRI studies also ex-
plored structural and functional brain differences before exposure
to systemic treatment. Of two studies assessing regional brain mor-
phology, one found lower gray matter (GM) density in patients
with BC before adjuvant treatment (McDonald and Saykin, 2013).
By contrast Deprez et al. (2012) did not ﬁnd differences in white
matter microstructure between patients with BC about to undergo
chemotherapy (pre-ChT+), patients with BC who do not require
chemotherapy (pre-ChT−), and no-cancer controls (NCs) after
correcting for depressive symptoms.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ences between patients with cancer and controls come from functional
MRI (fMRI) studies. These studies found a predominant pattern of
prefrontal hyperactivation and slightly lower or similar task perfor-
mance in patients with BC versus NCs before the start of adjuvant treat-
ment, suggestive of compensatory processes (Cimprich et al., 2010;
McDonald et al., 2012). One study found that higher levels of worry
were associated with lower cognitive performance and lower brain de-
activation in patients with BC (Berman et al., 2014). Three fMRI studies
assessing various cognitive functions in one sample of pre-ChT+ and
NCs showed that group differences in BOLD activation were dependent
on the speciﬁc cognitive test performed and the inclusion of several co-
variates, e.g. cortisol or days since surgery (López Zunini et al., 2013;
Scherling et al., 2011, 2012). These studies emphasize the potential
relevance of psychosocial and biological factors in cognitive and brain
function before the start of chemotherapy.
In summary, both neuropsychological and imaging studies point to
the potential existence of pretreatment cognitive and brain dysfunction
in patientswith BC. Psychological and biological mechanisms have been
proposed to underlie these impairments including surgical factors and
anesthesia, fatigue, comorbidities and cancer staging, but as yet no
studies determined and explained this phenomenon convincingly
(Ahles et al., 2008; Cimprich et al., 2010; Mandelblatt et al., 2014;
Wefel et al., 2004).
The current study sets out to build upon previous ﬁndings of cogni-
tive problems and changes in brain function and structure prior to
adjuvant treatment by combining neuropsychological testing, MRI,
and patient-reported outcomes (PROs). With this set-up, differences
in several data types can be related to each other and potential underly-
ing psychological factors can be identiﬁed.
2. Materials and methods
2.1. Subjects
Participants were patients with BCwho had undergonemastectomy
or lumpectomy and age-matched no-cancer controls (NC). Patients
were either scheduled to receive adjuvant anthracycline-based chemo-
therapy (pre-CHT+) or did not require chemotherapy (pre-CHT−).
Subjects were eligible if they met the following criteria: female, under
70 years of age, sufﬁcient command of the Dutch language, no previous
malignancies. Patients additionally had to have a diagnosis of primary
breast cancer, no distant metastases, and no other treatment than sur-
gery at the time of baseline assessment. NCs were recruited through
participants, as well as through advertisements in the participating
hospitals.
The study was approved by the Institutional Review Board of the
Netherlands Cancer Institute, serving as the central ethical committee
for all participating institutes. Written informed consent was obtained
according to the declaration of Helsinki and following institutional
guidelines. The experiment was conducted at the Academic Medical
Center of the University of Amsterdam and the Spinoza Centre for
Neuroimaging.
Follow-up data collection at approximately 6 months after comple-
tion of chemotherapy, or at matched intervals, is ongoing and will be
presented elsewhere.
2.2. Procedures
Seven questionnaires were administered to assess PROs, such as
health-related quality of life (QOL), anxiety and depression, mood,
stress, cognitive problems, and personality dimensions (Supplementary
Table 1). Premorbid verbal IQ was estimated with the use of the Dutch
Adult Reading Test (NART) (Schmand et al., 1992). A comprehensive
neuropsychological test battery was used, consisting of 18 test indices,
grouped into the domains of executive function, attention, visualmemory, verbal memory, processing speed, and motor speed
(Supplementary Table 2). Assignment into domains was determined
based on literature and no outcome could be present in more than
one domain.
To objectively assess long-term stress, hair samples were collected
and consequently analyzed by the Department of Biopsychology of
the Technische Universität of Dresden. Cortisol levels were deter-
mined in segments of 2 cm, representing a period of 2 months.
Wash and steroid extraction procedures are described elsewhere
(Kirschbaum et al., 2009).
MRI data were acquired using a 3.0 Tesla Intera full-body MRI scan-
ner (AMC Medical Center) and a 3.0 Tesla Achieva full-body MRI scan-
ner (Spinoza Centre for Neuroimaging) (Philips Medical Systems, Best,
The Netherlands). A SENSE 8-channel receiver head coil was used at
both locations.
An axial ﬂuid attenuated inversion recovery (FLAIR) scan (TR/TE/
TI = 11,000/100/2600 ms, FOV 230 × 230 mm, 27 slices, voxel size
0.9 × 1.4 × 5.0 mm, slice gap 0.5 mm) was acquired to score white
matter abnormalities with the visual rating score of Fazekas (range
0–3) (Fazekas et al., 1987). All ratings were performed by a neurora-
diologist (L.R.) blind to the clinical data. A T1 weighted three-
dimensional magnetization prepared rapid gradient echo (MPRAGE)
scan (TR/TE = 6.6/3.0 ms, FOV 270 × 252, 170 slices, voxel size
1.05 × 1.05 × 1.20 mm) was made for anatomical reference and
voxel-based morphometry (VBM). Single voxel proton MR spectrosco-
py (1H-MRS) was acquired in the left semioval center (SC) and the
left hippocampus (HC) to assess neurochemical properties of white
and graymatter respectively. The semioval center allows for data acqui-
sition in white matter alone and it has been shown to be vulnerable to
chemotherapy (De Ruiter et al., 2011). The hippocampus has previously
been shown to be affected by cancer treatment and is an interesting
brain structure because of its role in memory. The left side of the brain
was chosen because of its predominance in cognition. Fully automated
point resolved spectroscopy (PRESS) including global shimming
(voxel size = 6.0 ml for semioval center and 2.56 ml for hippocampus,
TR/TE= 200/35–40 ms, NSA= 64) was obtained. Diffusion Tensor Im-
aging (DTI) was acquired in 32 directions (TR/TE = 8136/94 ms, FOV
250 × 250 mm, 64 slices, voxel size 2.23 × 2.23 × 2.00 mm, b-value:
1000 s/mm2), covering the entire brain. Functional MRI acquisition
was based on T2* weighted gradient echo planar imaging (EPI) of 38
axial slices (voxel size 2.3 × 2.3 × 2.3 mm, interslice gap 0 mm, matrix
size 96 × 96, TR= 2.1 s, TE= 25ms).We acquired 230 volumes during
the Tower of London (ToL) task, 170 for memory encoding, and 125 for
memory retrieval.
Artrepair was used to detect and repair artifacts (Mazaika et al.,
2009). All fMRI preprocessing was performed using SPM8 (Statistical
Parametric Mapping; Wellcome Trust Centre for Neuroimaging,
London, UK). Slice timing correction was applied to the ToL and Re-
trieval images. All fMRI images were reoriented and realigned to
the ﬁrst volume. Individual T1 scans were segmented based on
gray matter, white matter, and cerebrospinal ﬂuid. Coregistered EPI
and T1 scans were normalized to the Montreal Neurologic Institute
(MNI) reference brain with the use of the segmentation parameters. Fi-
nally, smoothingwas applied using an 8-mm full-width half-maximum
Gaussian kernel.
An abbreviated version of the Tower of London (ToL) paradigm by
van den Heuvel et al. (2003) was used to assess prefrontal function.
During planning, ﬁve conditions ranging from one to ﬁve moves were
presented. A starting conﬁguration and a target conﬁguration were
displayed. Each consisted of three colored beads placed on three vertical
rods, which could accommodate one, two, and three beads respectively.
Subjects were instructed to determine the minimum number of steps
required to get from the starting to the target conﬁguration bymentally
moving the beads one at a time. In the baseline condition, the number of
yellow and blue beads had to be counted. The presentation of trials was
self-paced with a maximum duration of 1 min per trial. The task lasted
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speed. The task was practiced outside the scanner.
The Paired Associatesmemory taskwas based on a task paradigm by
Jager et al. and was shown to reliably activate the parahippocampal re-
gion (Jager et al., 2007). During associative learning, subjects were
asked to indicate if the person shown in the portrait photo was likely
to live in the home interior in the simultaneously presented picture.
The baseline condition consisted of three arrowheads pointing to
(“bbb” or “NNN”) indicating a left or right button press respectively.
The arrows were superimposed on blurred portrait and interior design
pictures to match the visual input of the associative learning condition.
The learning and baseline trials were presented in a block design.
For the learning condition, six blocks were presented with ﬁve trials
per block. Stimuli were presented for 5 s. The baseline condition
consisted of ﬁve blocks with ﬁve stimuli, which were presented
3 s. Directly after the learning part of the task, a recognition test
was administered. The baseline trials were the same as in the learn-
ing part. For the recognition part, all pictures from the learning
phase were shown and subjects were asked to indicate whether
they had seen the same combination of pictures before. Sixty per-
cent of the pairs were the same as in the learning phase. The order
of the trial types was pseudo-randomized. All stimuli were present-
ed for 4 s.
2.3. Statistical analysis
Demographic and clinical variables, PROs, neuropsychological data,
MR spectra, and fMRI performance data were analyzed with SPSS 20
(IBM, Armonk, NY) by means of ANOVA or chi-squared test, as appro-
priate. Age and IQ were included in neuropsychological and fMRI
analyses. Age and scanner location were included in analyses of all
MRI data. Corrections for multiple comparisons were applied and will
be speciﬁed per data type.
Neuropsychological data were analyzed in line with International
Cognition and Cancer Task Force (ICCTF) guidelines (Wefel et al.,
2011). Standardized z-scores for all test indices were calculated based
on the mean and standard deviation of the NC group. A cut-off for cog-
nitive impairment, based on the 95th percentile of the NCs, wasFig. 1. Flowdiagram: Selection of participants into the study. Pre-ChT+, patientswith BC before
no-cancer controls.identiﬁed as scores of two standard deviations below the mean on at
least three test indices (Schagen et al., 2006). The difference in propor-
tion of impaired subjects was tested using logistic regression.
In addition, the Mahalanobis Distance (MHD) was calculated as a
summary measure of overall performance (Crawford et al., 2012;
Crawford et al., 2012; Crawford et al., 2011; DeCarlo, 1997; Koppelmans
et al., 2012).MHD calculationswere based on residual scores, the differ-
ence between individual scores and the intercept, adjusted for age and
IQ. Residual scores that were greater than their respective mean score
were assigned a value of zero, so that negative scores could not be com-
pensated (Koppelmans et al., 2012). The residual scores of the control
groupwere used to calculate a variance–covariancematrix, correspond-
ing to the correlation between tests and the variance within the tests in
the control group (DeCarlo, 1997; Koppelmans et al., 2012). The vari-
ance–covariance matrix was then used to extract the unique variance
of each variable for each subject for all groups. Log2 transformation of
the resulting MHD was applied because of skewness of its distribution
and between group differenceswere calculatedwith an ANOVA. By tak-
ing into account the correlations between tests, MHD corrects for mul-
tiple comparisons. Domain scores and patient-reported outcomes were
corrected for multiple comparisons by lowering the critical p-value to
0.01.
Reaction time (RT) for fMRI tasks was calculated for correct trials.
For the ToL, all active versus baseline trials as well as a parametric
contrast with increasing task load (ToL Load) were modeled. For
the Paired Associates task, encoding trials were contrasted to base-
line trials, for retrieval, hits were contrasted to baseline. Group
differences for contrasts of interest were evaluated with random ef-
fects analyses.
MR spectroscopy was analyzed using a standard protocol within
LCModel (Provencher, 1993). The standard VBM8 pipeline within
SPM8 was used for analysis of MPRAGE images. For fMRI and VBM,
Whole-brain and ROI differences were considered statistically signif-
icant at a FWE corrected p-value of 0.05. DTI preprocessing and tensor
ﬁtting was performed within the FMRIB Diffusion Toolbox (FDT) (part
of FMRIBs Software Library (FSL) (Smith et al., 2006)). Diffusion data
were ‘skeletonized’ with Tract-based spatial statistics (TBSS, part of
FSL (Smith et al., 2006)) and nonparametrically tested (Nichols andchemotherapy; pre-ChT−, patientswith BCnot scheduled to undergo chemotherapy; NCs,
Table 1
Patient characteristics and self-reported outcomes.
Pre-ChT+
(n = 32)
Pre-ChT−
(n = 33)
NC
(n = 38)
p
Age (years) 50.2 (9.2) 52.4 (7.3) 50.1 (8.7) .442
Estimated IQ (NART) 100.6 (14.1) 102.8 (14.7) 107.0 (11.1) .120
Education level (n(%))b
Middle 4 (13) 5 (15) 1 (3)
High 28 (88) 28 (85) 37 (97)
Time since surgery (days) 36.1 (20.0) 31.5 (15.7) NA .308
Breast cancer stage (n(%))
0 13 (39)
1 20 (63) 18 (55)
2 11 (34) 2 (6)
3 1 (3)
n (%) n (%) n (%)
Pre-menopausal 19 (59%) 16 (49%) 20 (53%)
Post-menopausal 13 (41%) 17 (51%) 18 (47%) .674
Anti-diabetic medication 0 (0%) 2 (6%) 2 (5%)
Cardiovascular medication 6 (19%) 8 (24%) 9 (24%)
Psychotropic medication 5 (15%) 4 (12%) 2 (5%)
EORTC QLQ-C30
Physical functioningb 91.7 (11.4)* 88.1 (11.7)* 97.0 (7.1) .001
Role functioningb 66.1 (35.3)* 67.2 (29.0)* 95.2 (19.3) b.001
Social functioningb 80.2 (23.0)* 79.3 (24.3)* 97.8 (9.6) b.001
Cognitive functioningb 81.8 (24.1) 80.3 (24.8) 90.4 (14.8) .104
Global quality of lifec 75.8 (17.6)* 73.0 (15.6)* 87.1 (12.7) b.001
Paind 25.5 (27.4)* 27.8 (27.5)* 7.0 (13.2) b.001
Fatigued 24.7 (23.4) 34.3 (25.7)* 15.2 (19.4) .003
HSCL-25 13.5 (13.7) 11.6 (10.5) 7.7 (9.4) .09
PSS 24.3 (6.6)* 21.0 (7.5) 19.2 (5.4) .006
POMS
Fatigue subscalee 2.5 (3.9) 3.0 (4.8) 1.3 (1.5) .135
Vigor subscalef 12.0 (4.0)* 12.3 (3.4)* 14.6 (2.3) .001
Total scorese 17.4 (15.7) 15.4 (11.8) 9.6 (5.2) .014
MOS-cog 81.4 (16.4) 74.0 (15.4) 83.4 (11.9) .022
Values indicatemean± SD unless indicated otherwise. Pre-ChT+, patients with BC before
chemotherapy; pre-ChT−, patients with BC not scheduled to undergo chemotherapy;
NCs, no-cancer controls; NART, Dutch version of the National Adult Reading Test:
alow = primary school, middle = secondary school, high = university and graduate
school; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer
health-relatedQuality-of-life Questionnaire: scores range from0 to 100, higher score indi-
cates bbetter functioning, cbetter quality of life, or dmore symptoms; HSCL-25, Hopkins
Symptom Checklist-25: scores range from 0 to 100, higher score indicates higher levels
of anxiety and depression; PSS, Perceived Stress Scale: scores range from 10 to 50, higher
scores indicate higher levels of perceived stress; POMS, Proﬁle of Mood States, ehigher
scores indicatemore problems, flower scores indicatemore problems.MOS-cog, Cognitive
Functioning Scale of the Medical Outcomes Study, lower scores indicate more problems.
* Indicates a signiﬁcant difference with NC at p b .01
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plemental material).
Correlation analyses were only performed when signiﬁcant group
differences were found or when a strong relation was expected. In line
with existing literature, we calculated the following correlations.
Correlations between various PROs were examined. Neuropsycho-
logical performance (MHD, domain scores) was correlated with
PROs. Voxel based analyses for BOLD signal, GM volume and FA and
MD were performed within SPM8 and FSL to study associations
with speciﬁc PROs and neuropsychological performance. Whole-
brain FA andMD values were extracted, as well as BOLD signal in sig-
niﬁcantly different clusters and these were correlated with neuro-
psychological performance and PROs.
3. Results
3.1. Participants
A total of 285 participantswere eligible to participate in this study, of
which 137 participated in the study. Main reasons given for decline
were ‘too burdensome’ and ‘hesitant about MRI’. Four patients were
excluded because of incidental ﬁndings on MRI scans, 21 patients
were excluded because three or more scans of different modalities
were missing. The groups were matched on age and IQ leaving 32 pre-
ChT+, 33 pre-ChT−, and 38 NC subjects for our ﬁnal analyses (see
Fig. 1).
All patient characteristics and PROs are presented in Table 1. As
expected, no signiﬁcant differences were found between groups on
age and premorbid IQ. The patient groups also did not differ on time
since surgery.
3.2. Patient-reported outcomes
One-way ANOVA showed that the three groups differed on phys-
ical, F(2,100) = 7.0, p = .001, role, F(2,100) = 12.3, p b .001, and
social functioning, F(2,100) = 10.1, p b .001, global quality of life,
F(2,100) = 8.6, p b .001, and pain, F(2,100) = 8.2, p b .001 (as mea-
sured with the EORTC QLQ-C30). Post hoc analyses demonstrated
signiﬁcantly lower physical, role, and social functioning, lower global
QOL, and more pain in pre-ChT+ as well as pre-ChT− compared to
NC. A signiﬁcant difference in fatigue scores (EORTC QLQ-C30) was
found between the groups, F(2,100)= 6.2, p= .003, post hoc testing
showed more fatigue in pre-ChT− compared to NC, p= .001. A sim-
ilar pattern was seen in fatigue scores on the day of the assessment,
measured with the POMS, but this did not reach signiﬁcance. Pre-
ChT+ patients reported signiﬁcantly more stress than the control
group, F(2,100) = 5.5, p = .006. A trend was seen for patients
reporting more anxiety and depression (measured with the HSCL)
than controls. Both patient groups were signiﬁcantly less active
than the control group, as measured with the vigor subscale of the
POMS, F(2,100) = 7.2, p = .001. The patient groups indicated more
mood disturbances on the POMS total scores, which did not reach
signiﬁcance. None of the other PROs showed signiﬁcant differences
between groups.
3.3. Neuropsychological assessment
Log2 transformed MHD was signiﬁcantly different between the
groups, F(2,100) = 4.0, p = .021, indicating worse cognitive per-
formance in pre-ChT+ and pre-ChT− compared to controls (see
Table 2). However, when fatigue, perceived stress, or anxiety and
depression were included in the model, this difference was no longer
signiﬁcant. Domain scores and the proportion of cognitively impaired
subjects were not signiﬁcantly different between any of the groups
(Table 2).3.4. Task-related fMRI
Performance and mean reaction time on the ToL were not signif-
icantly different between the three groups (see Supplementary
Table 3). For both active versus baseline contrast and task load, all
groups showed robust activation of the dorsolateral prefrontal cor-
tex (DLPFC), premotor cortex, precuneus, posterior parietal cortex
(PPC), striatum, and cerebellum (see Supplementary Fig. 1 and Sup-
plementary Table 4). Whole-brain as well as ROI analyses showed no
signiﬁcant group differences for the active versus baseline contrast.
In the pre-ChT− versus the NC group we observed signiﬁcant hyper-
activation of the dorsomedial prefrontal cortex extending into the
DLPFC with increasing task difﬁculty (see Fig. 2 and Table 3). The
pre-ChT+ group demonstrated subthreshold hyperactivation at the
same location when compared to NC (see Fig. 2). These differences
were no longer signiﬁcant when fatigue scores were included in
the model, while other PROs did not elicit the same effect. ROI anal-
ysis did not show any differences between the groups.
Reaction time duringmemory encoding and retrievalwas not signif-
icantly different between groups, as was retrieval performance (see
Supplementary Table 3). The ventral stream (occipital areas and fusi-
form gyrus) extending into the parahippocampal gyrus and the hippo-
campus proper showed signiﬁcant activation across groups during
Fig. 2.Tower of London— task load contrast.Main task effect andgroup comparisonswith andw
corrected pfwe b .05; shown at p b .001, except for non-signiﬁcant difference pre-ChT+ NNC, sho
chemotherapy; pre-ChT−, patients with BC not scheduled to undergo chemotherapy; NCs, no
Table 2
Overall neuropsychological test performance, standardized cognitive domain scores and
raw test scores.
Pre-ChT+ Pre-ChT− NC p
MHD 3.92 (1.43) 3.94 (1.51) 3.09 (1.40) .021
% impaired 3 (9.4%) 2 (6.1%) 0 (0%) .432
Executive function −.30 (.95) −.12 (.84) 0 (.60) .485
COWAT 40.00 (10.92) 44.70 (11.73) 43.37 (10.29)
BADS zoo test 2.44 (1.29) 2.64 (1.17) 2.45 (1.16)
TMT Ba 69.13 (23.85) 70.39 (30.71) 60.18 (15.59)
Attention −.29 (.76) −.10 (.75) 0 (.64) .184
Flanker congruent trialsa 569 (48) 567 (52) 558 (42)
Flanker stimulus
incongruenta
578 (45) 575 (49) 567 (44)
Flanker response
incongruenta
595 (46) 594 (53) 586 (46)
VRT dominant handa 304 (38) 295 (32) 292 (39)
VRT non-dominant handa 333 (62) 310 (45) 309 (43)
Digit span 13.19 (3.11) 14.00 (3.81) 13.74 (3.24)
Visual memory −.28 (.68) −.33 (.82) 0 (.89) .411
WMS-R immediate recall 34.13 (2.32) 34.00 (3.62) 35.61 (3.70)
WMS-R delayed recall 31.38 (4.70) 30.97 (4.34) 32.13 (4.98)
Verbal memory .16 (.85) .02 (.91) 0 (.86) .420
HVLT immediate recall 28.31 (4.88) 28.15 (4.41) 27.45 (3.67)
HVLT delayed recall 10.06 (1.81) 10.00 (1.89) 10.00 (1.77)
HVLT delayed recognition 11.81 (0.47) 11.55 (0.75) 11.66 (0.78)
Processing speed −.34 (1.00) −.24 (.91) 0 (.86) .535
TMT Aa 33.84 (11.16) 31.64 (9.41) 31.32 (9.18)
Digit symbol substitution 71.75 (13.62) 71.01 (13.76) 76.95 (13.08)
Motor speed −.01 (1.03) −.51 (.74) 0 (.93) .077
Tapping dominant hand 63.5 (8.2) 59.7 (6.6) 63.4 (7.3)
Tapping non-dominant
hand
57.6 (7.3) 54.2 (5.2) 57.9 (7.3)
Values indicate mean± SD unless indicated otherwise. All analyses were adjusted for age
and IQ. Pre-ChT+, patients with BC before chemotherapy; pre-ChT−, patients with BCnot
scheduled to undergo chemotherapy; NCs, no-cancer controls; MHD, Mahalanobis
Distance, higher score indicates worse overall cognitive performance; domain scores are
expressed as z-scores, neuropsychological test scores are raw scores.
a Higher scores indicate worse performance.
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ing retrieval, the ventral and dorsal stream, and parahippocampal
gyrus were signiﬁcantly activated. Whole brain and ROI analyses re-
vealed no signiﬁcant group differences during encoding and retrieval.
3.5. Structural MRI
Whole brain analyses of regional GM and white matter volume
showed no signiﬁcant differences. GM volume of ROIs in the DLPFC
and superior parietal cortex was not signiﬁcantly different between
groups. Voxel-based analyses showed widespread lower FA and higher
MD in both patient groups compared to NCs, indicating lower white
matter integrity (see Fig. 3 and Supplementary Table 5). The differences
in FA were no longer signiﬁcant when fatigue, but not other PROs, was
added to the model.
3.6. Other variables
Cortisol concentrations were not signiﬁcantly different between
groups for the previous 2 months, F(2,92) = 2.2, p= .118, and for the
previous two to four months, F(2,88) = 1.7, p= .190 (see Supplemen-
tary Table 6). 1H-MRS data (see Supplementary Table 7) and Fazekas
ratings for white matter lesions, χ2(4) = 5.36, p = .252, (see Supple-
mentary Table 8) did not show signiﬁcant differences between groups.
3.7. Correlations
Performance on the verbal memory domain was signiﬁcantly corre-
lated with HSCL depression scores, r = –.269, p = .006. Processing
speed was signiﬁcantly correlated with physical functioning, r= .290,
p = .003, emotional functioning, r = .334, p = .001, global QOL,
r = .339, p = .001, and fatigue, r = –.292, p = .003, subscales of
EORTC QLQ-C30, HSCL anxiety, r = –.293, p = .003, PSS, r = –.334,
p = .001, mood, r = –.418, p b .001, and cognitive complaints, r =
.260, p= .008. MHDwas signiﬁcantly correlated with emotional func-
tioning, r = –.295, p = .003, social functioning, r = –.293, p = .003,ithout fatigue as a covariate (differenceswere considered statistically signiﬁcant at cluster-
wn at p b .05; brighter colors indicate higher T-values); pre-ChT+, patients with BC before
-cancer controls.
Table 3
fMRI coordinates of signiﬁcantly different cluster and clusterswith signiﬁcant correlations.
ToL task load Region R/L MNI
coordinates
Cluster
(k)
t value z value
x y z
Pre-ChT− N NC Dorsomedial
PFC
R 32 20 48 274 4.18 3.99
R 22 20 52 274 3.98 3.81
R 22 28 50 274 3.69 3.55
Positive correlation
fatigue
Dorsomedial
PFC
R 36 16 52 41 3.76 3.62
R 32 26 50 41 3.49 3.37
BOLD activations (MNI coordinates) for the Tower of London (ToL) task load contrast
group differences between pre-ChT−, patients with BC not scheduled to undergo chemo-
therapy and NCs, no-cancer controls. R, right; L, left; PFC, prefrontal cortex. Group differ-
ences are reported at cluster-corrected pfwe b 0.05, correlations are reported at p b 0.001.
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scales of EORTC QLQ-C30, mood, r= .261, p= .008, and cognitive com-
plaints, r = –.277, p = .005. No signiﬁcant correlations were found
between cortisol levels and self-reported outcomes or test performance.
A signiﬁcant correlation between fatigue and ToL task load BOLD activa-
tion across all groups was found in the dorsomedial prefrontal cortex
(see Fig. 4 and Table 3). None of the other factors was signiﬁcantly
associated with BOLD signal in any of the tasks. Voxel-based analyses
did not show signiﬁcant correlations between FA and MD and PROs or
MHD.
4. Discussion
To the best of our knowledge, this is the ﬁrst study combining
different MRI modalities, neuropsychological assessment, and PROs to
evaluate pretreatment cognitive function and potential mediating
factors in patients with various disease stages. Our ﬁndings show
worse cognitive performance, prefrontal hyperactivation, and lower
white matter integrity in breast cancer patients compared to no-
cancer controls, and revealed fatigue as an important factor contributing
to these results. No signiﬁcant differences in regional brain volume or
brain metabolites were found. Although sample size of the current
study was relatively large, insufﬁcient power might still have played a
role considering the arguably subtle effects of various aspects of cancer
and treatment on MRI measures.
In agreement with some earlier reports, lower cognitive perfor-
mance was observed in patients with BC compared to no-cancer
controls, but only on a summary measure of cognitive performance
and not when group means or percentages of impaired participantsFig. 3.Group differences in skeletonized FA andMD,with andwithout fatigue as a covariate (sh
yellow indicates lower statistical signiﬁcance).were compared. This ﬁnding suggests that small deviations across
several tests account for the currently observed lower cognitive
performance.
Our fMRI ﬁndings of prefrontal hyperactivation in patients with BC
versus NC during a task of executive function support earlier results
and might point to a speciﬁc vulnerability of these areas to the effects
of cancer and its treatment. Brain hyperactivation has been reported
to be due to compensation for white matter damage (Daselaar et al.,
2013). Indeed, the patients with BC had widespread lower brain white
matter integrity compared to healthy controls. The ﬁnding that patients
with cancer also differ in their microstructural integrity compared to
controls before the start of therapy is new. The only other DTI study ob-
served no differences in white matter integrity between patients with
BC and NCs when controlling for depression score, but whether the
groups differed when these depression scores were not included was
not reported (Deprez et al., 2012).
Interestingly, pre-ChT− patients were most deviant on PROs, brain
activation and white matter integrity. As their disease is on average
less advanced, these ﬁndings make it unlikely that cancer staging was
driving the differences between the two patient groups. However, two
previous studies have foundan association betweendisease progression
and cognitive function (Ahles et al., 2008; Mandelblatt et al., 2014).
Combining the results of these studies, the role of cancer staging in cog-
nitive dysfunction remains uncertain.
A second possible explanation for our ﬁnding of pretreatment differ-
ences might be the side effects of breast surgery or anesthesia. Since
both our patient groups had undergone surgery, we could not study
this relation directly but looked at time since surgery as a surrogate. Un-
like some previous studies (López Zunini et al., 2013; Scherling et al.,
2012), we did not ﬁnd a relation between time since surgery and any
of the outcome measures. A general limitation of our study is the lack of
a pre-surgery assessment. Breast cancer surgery has previously been
found to be associated with lower cognitive performance (Hedayati
et al., 2011). These ﬁndings indicate that future studies should preferably
include a pre-surgery assessment to rule out effects of anesthesia or other
surgical factors.
A third factor that could be put forward to explain pretreatment
differences, is the higher levels of comorbidity in cancer patients than
NC. One report showed that higher rates of comorbiditieswere associat-
ed with cognitive impairment (Mandelblatt et al., 2014). However,
patients in that study were on average 15 years older than those in
the current sample. Also, the levels of comorbidities were considerably
higher than in our sample, as indicated by low levels of medication
use in the current sample.own at ptfce b .05; green,whitematter skeleton; red indicates higher statistical signiﬁcance,
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sons for participation between the patient groups. About half of the eli-
gible participants were willing to participate in our study, without
differences between the patient groups, and no differences were
observed with respect to relevant demographics. Still, patients facing
chemotherapy are clearly in a different stage of their overall therapy
plan than patients for whom chemotherapy is not required. These
differences may inﬂuence both symptom perception and expression.
Patients who have an intense cancer treatment ahead might still oper-
ate in ‘survival mode’. Patients who do not have the prospect of being
exposed to chemotherapy might, in contrast, already have moved to
another mental state where they allow negative emotions associat-
ed with the disease to surface. Also, it could be that patients not re-
ceiving chemotherapy feel that the study is less relevant to them.
This could lead to a potential bias in the motivation to participate,
with more patients already experiencing cognitive problems in the
pre-CHT− group, without inﬂuencing participation rates per se.
As mentioned before, symptoms of fatigue appear to be related to
the observed impairments in patients with BC compared toNCs. Fatigue
levels were markedly higher in cancer patients than in controls. Group
differences in cognitive function and various MRI measures did not
survive our stringent statistical thresholding when the analyses were
adjusted for fatigue levels. Furthermore, fatigue levels were modestly
but statistically signiﬁcantly associated with cognitive function and
fMRI.Fig. 4. Signiﬁcant correlation BOLD signal ToL task load contrast and fatigue over all groups
(shown at p b .001; brighter colors indicate higher T-values).Higher levels of fatigue in patients with cancer compared to the
general population are a common ﬁnding (Hofman et al., 2007). Pro-
inﬂammatory cytokines have been associated with cancer-related
fatigue (Bower et al., 2011). Moreover, pro-inﬂammatory cytokines
are frequently proposed as a possible mechanism underlying cancer-
related cognitive dysfunction but clinical studies have not yet shown a
clear picture regarding cytokines, cognition and/or fatigue and the
way in which these factors may inﬂuence one another (Cheung et al.,
2013; Vardy et al., 2014). It might be that elevated levels of pro-
inﬂammatory cytokines cause fatigue as well as cognitive problems
without a direct relation between the two factors. Another explanation
could be that fatigue leads to changes in cerebral blood ﬂow which in
turn leads to changes in brain function and structure and consequently
has an effect on cognitive function (Ocon, 2013).
In order to obtain a better insight into the wide era of factors that
seem to be relevant for pre-treatment cognitive function, assessment
of key aspects of health-related quality of life, i.e. fatigue and distress,
has to be taken into account in neuroimaging and neuropsychological
studies in patients with cancer.
A major strength of this study is the comprehensive coverage of
various outcomemeasures in one report including differentMRImodal-
ities, neuropsychological assessment, and patient-reported outcomes.
By combining the data and studying different important factors we
present a complete assessment of cognitive dysfunction associated
with cancer and treatment. Further, the current study encompasses
data froma relatively large sample of patientswith BC. This large sample
size together with consequent correction for multiple comparisons
strengthens the results presented here.
To conclude, our ﬁndings show worse cognitive performance, pre-
frontal hyperactivation, and lower white matter integrity in breast can-
cer patients compared to no-cancer controls. These results were related
to fatigue. The role of fatigue in our data suggests cancer-related psy-
chological or biological processes to negatively inﬂuence cognitive func-
tioning and associated aspects of brain structure and function. Because
even mild cognitive problems can have functional consequences
(Marcotte et al., 2010), these ﬁndings should be further investigated
in speciﬁc hypothesis-driven studies. Our results show the importance
of the use of PROs to understand cognitive problems BC patientsmay al-
ready experience before treatment. By further studying these problems,
it might be possible to identify patients at risk of developing cognitive
dysfunction and determine underlying processes that could be used as
a target for interventions.
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